Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lenvima
Pharma
Merck's Welireg surprisingly fails in first-line kidney cancer
Welireg's phase 3 flop in first-line kidney cancer comes as a surprise following two late-stage trial wins in the second-line and adjuvant settings.
Angus Liu
Apr 21, 2026 10:00am
Merck's Welireg combos deliver 1-2 punch to kidney cancer
Feb 28, 2026 10:00am
Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia
Oct 31, 2025 8:20am
Merck, Eisai call it quits on Keytruda-Lenvima in liver cancer type
Oct 29, 2025 11:32am
Merck, Eisai combo misses survival goal in GI cancer trial
Jan 24, 2025 10:26am
Daiichi, Eisai, Granules—Fierce Pharma Asia
Sep 20, 2024 10:16am
